RxDoctor Payments Data

Siva Yechoor, MD

Psychiatry · Sylvania, OHNPI 1538179890

Payments from drug & device makers

$7,111in general payments, 2019–2025

Across 405 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$755
  • Otsuka America Pharmaceutical, Inc.$576
  • Axsome Therapeutics, Inc.$442
  • Takeda Pharmaceuticals U.S.A., Inc.$375
  • Neurocrine Biosciences, Inc.$362
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,81496%
  • Education$2974%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,111 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$123,635
Medicare patients
131
Services billed
3,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate32$255,963
TrintellixVortioxetine Hydrobromide91$54,820
SpravatoEsketamine Hcl46$54,257
VraylarCariprazine Hcl26$41,241
Invega SustennaPaliperidone Palmitate15$39,448
RexultiBrexpiprazole15$21,709
Vilazodone Hcl162$16,603
Desvenlafaxine Succinate ErDesvenlafaxine Succinate172$10,741
Lisdexamfetamine Dimesylate38$10,094
BelsomraSuvorexant23$9,804
Aripiprazole174$8,630
VyvanseLisdexamfetamine Dimesylate19$7,494
Bupropion XlBupropion Hcl239$4,811
Eszopiclone207$4,801
Duloxetine Hcl224$4,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$362$255,96332 claims
Johnson & JohnsonSpravato, Invega Sustenna$40$93,70561 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$375$62,314110 claims
AbbVieVraylar$1,139$41,24126 claims
Otsuka America Pharmaceutical, Inc.Rexulti$576$21,70915 claims
MerckBelsomra$158$9,80423 claims
Lilly USA, LLCOlanzapine$203$1,33654 claims
Almatica Pharma LLCSertraline Hcl$38$87498 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Sylvania

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →